ISEND May Predict Clinical Outcomes for Advanced NSCLC Patients on PD-1/PD-L1 Inhibitors but Not Chemotherapies or Targeted Kinase Inhibitors

被引：0

作者：

Park, W. ^{[1
]}

Kwon, D. ^{[2
]}

Desai, A. ^{[1
]}

Florou, V. ^{[1
]}

Saravia, D. ^{[3
]}

Warsch, J. ^{[4
]}

Chae, Y. K. ^{[5
]}

Ishkanian, A. ^{[6
]}

Jahanzeb, M. ^{[7
]}

Mudad, R. ^{[8
]}

Lopes, G. ^{[9
]}

机构：

[1] Univ Miami, Sylvester Comprehens Canc Ctr, Hematol & Oncol, Miami, FL USA

[2] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Med Biostat & Bioinformat, Miami, FL USA

[3] Univ Miami, Miller Sch Med, Internal Med, Miami, FL 33136 USA

[4] Univ Miami, Sylvester Comprehens Canc Ctr, Radiol, Miami, FL USA

[5] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Dev Therapeut Program, Chicago, IL 60611 USA

[6] Univ Miami, Sylvester Comprehens Canc Ctr, Radiat Oncol, Miami, FL USA

[7] Univ Miami, Sylvester Comprehens Canc Ctr, Med Oncol, Miami, FL USA

[8] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[9] Univ Miami, Sylvester Comprehens Canc Ctr, Global Oncol, Miami, FL USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

Predictive; PD-1; inhibitor; Clinical outcome;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.07-024

引用

页码：S2004 / S2004

页数：1

共 50 条

[41] Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
Jelinek, Tomas
Paiva, Bruno
Hajek, Roman
FRONTIERS IN IMMUNOLOGY, 2018, 9
[42] Progress on biphenyl derivatives as PD-1/PD-L1 inhibitors
Shurong Wang
Yuli Wang
Hong Yan
Medicinal Chemistry Research, 2023, 32 : 2089 - 2115
[43] Combinations of Chemotherapy and PD-1/PD-L1 Inhibitors in Sarcoma
Lynch, Meghan M.
Alexiev, Borislav A.
Schroeder, Brett A.
Pollack, Seth M.
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (12) : 1861 - 1876
[44] Progression patterns in patients with advanced hepatocellular carcinoma treated with local therapy, targeted drugs, and PD-1/PD-L1 inhibitors
Zhao, Yanan
Wu, Di
Yao, Quanjun
Yuan, Hang
Hu, Hongtao
Li, Hailiang
CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 49 (02) : 147 - 154
[45] An update on companion and complementary diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC
Jorgensen, Jan Trost
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2021, 21 (05) : 445 - 454
[46] Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC
Li Jiang
Fuchun Guo
Xiaoke Liu
Xiaoyu Li
Qing Qin
Pei Shu
Yi Li
Yongsheng Wang
Scientific Reports, 9
[47] Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC
Jiang, Li
Guo, Fuchun
Liu, Xiaoke
Li, Xiaoyu
Qin, Qing
Shu, Pei
Li, Yi
Wang, Yongsheng
SCIENTIFIC REPORTS, 2019, 9 (1)
[48] Plasma soluble PD-1/PD-L1 for prediction of prognosis in NSCLC patients treated with immune checkpoint inhibitors
Himuro, Hidetomo
Nakahara, Yoshiro
Igarashi, Yuka
Kouro, Taku
Murakami, Shuji
Wei, Feifei
Horaguchi, Shun
Tsuji, Kayoko
Mano, Yasunobu
Saito, Haruhiro
Azuma, Koichi
Sasada, Tetsuro
CANCER SCIENCE, 2024, 115 : 1381 - 1381
[49] The association between BIM deletion polymorphism and treatment efficacy of PD-1/PD-L1 inhibitors in advanced NSCLC.
Zhang, Dai
Li, Xuanzong
Huang, Caimei
Fan, Xinyu
Qin, Wenru
Yang, Linlin
Wang, Linlin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[50] Inside PD-1/PD-L1,2 with their inhibitors
Boisgerault, Nicolas
Bertrand, Philippe
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 256

← 1 2 3 4 5 →